2
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Patient Satisfaction
2
Urologic Neoplasms
1
Thyroid Cancer, Papillary
1
Sarcoma, Ewing
1
Sarcoma
1
Radiation Injuries
1
Patient Preference
1
Patient Acceptance of Health Care
1
Osteosarcoma
1
Osteitis Deformans
1
Neoplasms
1
Breast Neoplasms
1
Bone Neoplasms
1
Interventions
Gemcitabine
9
pembrolizumab
7
Cisplatin
5
enfortumab vedotin
4
atezolizumab
4
Trastuzumab
4
Mitomycin
4
Carboplatin
4
Sunitinib
3
Pemetrexed
3
dodecyl maltoside
2
cabozantinib
2
Water
2
Sugammadex
2
Standard of Care
2
Saline Solution
2
Paclitaxel
2
Nivolumab
2
Neostigmine
2
Docetaxel
2
Cetuximab
2
Bevacizumab
2
zidovudine 5'-monophosphate-mannose-albumin conjugate
1
vinflunine
1
valrubicin
1
tucatinib
1
tislelizumab
1
testosterone 17 beta-cypionate
1
temsirolimus
1
relatlimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urologic Neoplasms
×
delta 24-sterol reductase
×
Clear all
NCT04590976
2023-02-08
IP5-MATTER
Imperial College London
Completed
320 enrolled